NATCO Pharma Gets Approval For ₹1,279.36 Crore Rights Issue At ₹750 Each

Market snapshot: NATCO Pharma Limited has received board approval to finalize the terms of its rights issue. The company will raise ₹1,279.36 crore by issuing 1,70,58,082 fully paid-up equity shares at ₹750 per share.

Data Snapshot

• Total proposed rights issue capital raising of ₹1,279.36 crore.
• Offering price of ₹750 per rights equity share of face value ₹2.
• Issuance of 1,70,58,082 equity shares to eligible shareholders.

What's Changed

• The board has formally approved the specific issue size of ₹1,279.36 crore, aligning with the initial cap of up to ₹1,300.00 crore proposed on September 9, 2026.
• Specific terms including the rights entitlement ratio and record date are being implemented following in-principle exchange approvals on September 21, 2026.

Key Takeaways

• Targeted Debt Reduction: A major portion of the proceeds (₹810.50 crore) is allocated toward the prepayment or repayment of the company's outstanding borrowings.
• Sustained R&D Allocation: The company will channel ₹110.00 crore from the net proceeds into research and development initiatives.
• Exchange Approvals Secured: NATCO obtained the essential in-principle clearances from both the BSE and NSE on September 21, 2026.
• Consolidated Cash Positioning: De-leveraging via rights issue leaves NATCO's existing cash reserves of approximately ₹1,400.00 crore intact for future growth.

SAHI Perspective

NATCO Pharma's decision to utilize 63.35% of the proceeds (₹810.50 crore) for de-leveraging is structurally positive. By paying down outstanding borrowings, the company will secure significant interest cost savings. This allows NATCO to deploy internal cash flows toward its high-potential R&D initiatives, while keeping its ₹1,400.00 crore cash reserve liquid for strategic international acquisitions.

Market Implications

The equity dilution of 1.70 crore shares may lead to minor, short-term EPS adjustments. However, the overall market sentiment is expected to remain supportive due to the significant debt reduction, strengthening NATCO's long-term balance sheet health.

Trading Signals

Market Bias: Bullish

The structured de-leveraging of ₹810.50 crore combined with ₹110.00 crore in dedicated R&D expansion establishes a strong balance sheet runway.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Prepayment of ₹810.50 crore in borrowings to lower financial costs.
• Clinical or launch progress in NATCO's US pipeline of 28 Para-IV assets.
• Outcome of USFDA observations at the Visakhapatnam unit.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian pharmaceutical sector continues to witness strong momentum in complex generic drug launches and domestic price optimization. NATCO's strategy of offering high-value generics at aggressive price points aligns with the sector's overarching shifts toward generic accessibility.

Key Risks to Watch

• Regulatory Headwinds: The company's manufacturing unit in Visakhapatnam received a Form 483 with 4 observations in August 2026, which remains a key monitorable.
• Short-term Dilution: The addition of 1,70,58,082 equity shares expands the outstanding share capital and may cause near-term EPS dilution.

Recent Developments

In August 2026, NATCO Pharma's Visakhapatnam plant was issued a Form 483 with four observations by the USFDA. Additionally, the Supreme Court of India cleared the decks for NATCO's local generic launch of the spinal muscular atrophy drug Risdiplam at a competitive price of ₹15,900 per bottle, dismissing Roche's appeal.

Closing Insight

By pricing this rights issue at ₹750, NATCO has created an attractive entry or accumulation window for existing shareholders. The underlying rationale—swapping debt for equity while safeguarding immense organic cash piles—protects the firm's strategic flexibility.

High Performance Trading with SAHI.